Trials / Completed
CompletedNCT03607487
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB054707 | INCB054707 tablet administered orally once daily at the protocol-defined dose. |
| DRUG | Placebo | Placebo tablet administered orally once daily. |
Timeline
- Start date
- 2018-10-15
- Primary completion
- 2019-08-13
- Completion
- 2019-08-13
- First posted
- 2018-07-31
- Last updated
- 2025-08-21
- Results posted
- 2020-09-21
Locations
13 sites across 3 countries: Canada, Denmark, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03607487. Inclusion in this directory is not an endorsement.